Prostate cancer has undergone a stage migration since the advent of widespread PSA testing, yet still a significant number of men develop PSA recurrence following radical prostatectomy. This causes anxiety to the patient and the urologist. This review examines the clinical significance of biochemical relapse and the role of imaging modalities and anastomotic biopsies. The importance of the radical prostatectomy pathological features and the PSA kinetics in determining the site of recurrence and the best treatment modality is emphasised. The optimal timing and dose of salvage radiotherapy and the role of hormonal therapy is discussed.
Introduction
The incidence of prostatic cancer has remained fairly static over the last 8-10 years, while the proportion of men with recurrent disease after radical prostatectomy has fallen. The advent of PSA testing in the late 1980s has resulted in more men being diagnosed and treated with lower stage disease, both in the US and in Europe. 1 The proportion of men from the radical prostatectomy databases held at University College London with organconfined disease rose significantly, from 30% between 1988 and 1991 to over 50% in 2001(Po0.001).
2 Despite this 'stage migration', 27-53% of men will develop prostate-specific antigen (PSA) recurrence up to 10 years after radical prostatectomy 3 and 16-35% of patients receive second-line treatment within 5 years of surgery. 4, 5 Half of the men treated for recurrent disease after radical prostatectomy receive external beam radiotherapy (EBRT) to the prostatic bed, with curative intent. In contrast, over 90% of men with relapse following radical radiotherapy receive palliative hormonal manipulation. This reflects the limited therapeutic options for patients who have had radical radiotherapy or brachytherapy, though this may change with the increasing role of salvage cryotherapy, salvage brachytherapy and in some cases, salvage prostatectomy.
Definition and timing of relapse
There is no universally agreed PSA cut off to define 'recurrent disease' after radical prostatectomy. This is because different assays have differing sensitivities and the contribution of residual benign glands to a postoperative PSA remains unresolved, though residual benign glands are unlikely to result in PSA increases 40.2 ng/ml. 6 One of the most popular assays, the Hybritech (Tandom-R), has a detection threshold of 0.1 ng/ml. Using this assay, Epstein et al 7 proposed a cut off as X0.2 ng/ml, given that 53% of men with this PSA value eventually developed clinical progression. Lange et al 8 proposed a higher cut off of 0.4 ng/ml as all men with a postoperative PSA at this level had detectable disease progression within 6-49 months of surgery. The introduction of ultrasensitive assays that are able to detect PSA to 0.01 ng/ml means that men are diagnosed and treated for recurrence before their PSA reaches 0.1 ng/ml. 9 While at this level, potentially curative treatment is expedited, there is at least a theoretical risk of treating residual benign glands only.
Following surgery, the PSA should fall to undetectable levels within 4 weeks, given the half-life of PSA is 3.15 days. 10 A PSA nadir that is not 'undetectable' represents either residual benign tissue or local/metastatic malignant prostatic tissue. A rising PSA following a detectable nadir is likely to represent metastatic disease.
The seminal paper by Pound et al 3 demonstrated the extended period between biochemical failure after RP and the development of clinical progression. The median time for 315 of the 1997 men to develop PSA relapse, defined as a serum value of at least 0.2 ng/ml, was 2.3 years. Of 34% of these men who subsequently developed metastases, the median actuarial time to do so was 5 years from the time of PSA progression. Once men developed metastases the median time to death was just under 5 years. 3 The probability and time to develop metastases was dependent on the Gleason score (5-7 or 8-10), the time for biochemical progression (42 or p2 years) and the PSA doubling time (X10 or o10 months). Using these variables, 'Pound tables' have been constructed to predict the likelihood of clinical disease progression in men with biochemical recurrence after RP.
Site of relapse
The decision of what and when to treat depends on whether disease progression is confined locally to the prostatic fossa or whether distant spread has occurred. Local relapse alone occurs in 50% of cases and metastases with or without local recurrence in 50%. 11 Clinical and imaging modalities currently available are not of sufficient sensitivity to detect low volume local disease. The digital rectal examination is not useful if men have an undetectable PSA 3, 12 and is only sensitive once the PSA has been elevated for a median 2.3 years after surgery. Less than 5% of bone-scans are positive until the PSA value is above 40-45 ng/ml. 13 CT scans are not sufficiently sensitive at detecting local recurrence until the PSA is increasing by a rate of more than 20 ng/ml per year.
14 Advancements are being made combining the anatomical information from a CT with the functional data from PET scanning using 11 C-choline, though larger trials with longer follow-ups are required. The sensitivity and specificity of MRI and MR spectroscopy is improving, though it remains most sensitive at detecting nodal and bony metastases. 15, 16 The role of evolving technologies such as 111 Indium capromab scanning in the diagnosis of recurrent disease has yet to be established.
The use of transrectal ultrasound (TRUS)-guided anastomotic biopsies remains controversial and no biopsy protocol is agreed. Several series have identified poor sensitivity using this technique in men with a PSA o1.0 ng/ml, the level at which salvage radiotherapy is most efficacious. [17] [18] [19] In a series from the University of California, 54% of 114 men with persistently elevated PSA undergoing TRUS and anastomotic biopsy had confirmed local recurrence, though a third of men required more than one biopsy session. 17 In this study, the median PSA level of men with local recurrence was 5.7 ng/ml (range 0.2-35). Shekarriz et al 18 found only 25% of patients with a PSA of p1.0 ng/ml had a positive biopsy compared with 71% of those with a PSA 41.0 ng/ml. Saleem et al 19 reported none of the 11 patients with normal DRE and a PSA p0.5 ng/ml had a positive biopsy. Scattoni et al 20 reported men undergoing 6-8 anastomotic biopsies following a PSA recurrence or abnormality on DRE. No patients had evidence of metastatic disease on bone-scan or abdominal CT. In 68 men with a PSA 1.0 ng/ml or below, 45% had biopsies containing tumour.
From our own series of anastomotic biopsies in patients with a median PSA of 0.6 ng/ml (range 0.2-6.2), 33% of 12 cases were positive for cancer recurrence. 21 In a further five patients with negative biopsies the PSA stabilised after prostate bed radiotherapy, suggesting a high false-negative rate. In addition, in five patients salvage radiotherapy for local recurrence was delayed by benign anastomotic biopsies. These studies highlight the lack of sensitivity of TRUS and anastomotic biopsies at low PSA values at the time salvage radiotherapy is most effective. Anastomotic biopsies are usually unwarranted, a positive result does not exclude metastatic disease and a negative result does not exclude local recurrence. Furthermore, a positive anastomotic biopsy is not associated with improved outcome after salvage radiotherapy 22 and 10-40% of patients with a negative biopsy and a PSA o1.0 ng/ml show a PSA decrease after salvage radiotherapy, suggesting the presence of undetected local recurrence. 23 The best predictors of local vs metastatic recurrence are the pathological findings of the radical prostatectomy specimen and the postoperative PSA parameters. Patients with Gleason grade X8 disease, positive seminal vesicles or lymph node metastases have a 95, 86 and 100% likelihood of developing metastatic disease, respectively. 24, 25 Conversely, biochemical relapse is more likely due to local failure alone if there are multiple positive surgical margins, extensive extracapsular disease, Gleason score p7 and an absence of nodal or seminal vesicle involvement. 17, [26] [27] [28] Table 1 shows the Johns Hopkins' data comparing the pathological and PSA parameters in men with local or metastatic7local relapse.
The PSADT is a useful marker of local vs distant recurrence after radical prostatectomy. 3 Reproduced with kind permission from AW Partin.
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Lack of a PSA nadir below undetectable levels and PSA recurrence within 1-2 years of surgery all reduced the likelihood of remaining PSA-free after salvage radiotherapy. 32, 33 In general, men who develop PSA recurrence within 1-2 years of surgery, have tumour grade greater than 7, higher pathological stage, positive seminal vesicles or lymph node involvement, are more likely to harbour metastatic disease and are better suited to systemic treatment. 1, 3, 11, [32] [33] [34] [35] The problem lies in the men with an intermediate risk of metastatic disease. For these men nomograms, artificial neural networks or biostatistical equations incorporating the pathological and PSA features, and in some cases race, may be used to predict disease failure. [36] [37] [38] While these are cumbersome to use in the clinic, some are now available on the internet and may facilitate the management of borderline cases.
Treatment of relapse
The main management options available in patients who have biochemical failure after radical prostatectomy include active surveillance, prostate bed EBRT and hormonal manipulation. Attempts are being made to use salvage brachytherapy, 39 chemotherapy and highintensity focused ultrasound 40 in the management of local recurrence, though currently these techniques remain experimental. The decision on whether to treat or observe a patient with PSA only recurrence depends on the risks of clinical failure, perhaps aided by the Pound tables or biostatistical equations outlined above. In an AUA questionnaire in 1998, only 13% of urologists reported that they would offer salvage radiotherapy following an asymptomatic PSA rise, 54% preferred observation and 31% opted for hormonal manipulation. 41 This is because the role of external beam radiotherapy in men with PSA recurrence after radical prostatectomy remains unresolved and the subject of ongoing research. To date no randomised study has been reported and small retrospective case series with limited follow-up have been conflicting. This is partly due to variation in patient selection, differing definitions of biochemical failure, differences in radiation dose and variation in the use of adjuvant hormonal manipulation.
Studies reported highlight predictive factors that determine biochemical recurrence-free rates after salvage radiotherapy. Essentially where there is a high risk of metastases the likelihood of curative salvage treatment is reduced. The timing and dose of radiotherapy also impacts on PSA-free survival.
The importance of the radical prostatectomy Gleason grade in men undergoing salvage radiotherapy was demonstrated in several studies. 33, 42, 43 In 57 patients, reported from the University of Michigan, with a median follow-up of 7 years, the 5-and 8-year biochemical disease-free survival was 58 and 37%, respectively. 42 The only significant risk factor for progression was the Gleason score. At 8 years biochemical-free survival for Gleason score 2-6, 7, 8-10 was 48, 37% and 0%, respectively. 42 Cadeddu et al 33 reported no patients with Gleason score 9 or more, seminal vesicle invasion or lymph node metastases were PSA-free 2 years after salvage radiation.
The number of adverse risk factors also impacts on PSA-free survival. In 115 men receiving salvage radiotherapy for PSA recurrence or clinical local recurrence, 70 patients had radiotherapy and 45 men had neoadjuvant hormones before radiotherapy. 44 The 4-year PSA relapsefree survival was 77% if men had positive surgical margins and no poor prognostic features, compared with 20% if they had one or more poor prognostic feature including seminal vesicle involvement, a pre-radiotherapy PSA40.6 ng/ml or extracapsular disease. In patients receiving radiotherapy alone, 39% were recurrence-free compared with 59% for those on combined radiotherapy and neoadjuvant treatment. Other studies have failed to show an improvement in PSA outcome with neoadjuvant treatment. 44 The role of adjuvant hormonal manipulation in salvage radiotherapy after radical prostatectomy remains unresolved. This issue has been addressed in a randomised study, the Radiation Therapy Oncology Group (RTOG) 9601. This study is awaiting further follow-up before reporting.
Patients who receive radiotherapy after surgery fare better if the PSA falls to an undetectable level compared with those with a persistently detectable PSA (66% at 40 months compared with 20% at 12 months, respectively). 45 What is more, men in whom the PSA rises more than 1 year after surgery have a better response to salvage EBRT. 32, 33, 45, 46 The PSA level to initiate salvage treatment is critical in terms of radiotherapy efficacy. The American Society of Therapeutic Radiology and Oncology (ASTRO) Consensus Panel recommended salvage EBRT be given when the PSA level is less than 1.5 ng/ml. 47 Nudell et al 27 reported a cohort of 105 men treated with either adjuvant or salvage EBRT. The authors defined disease-free as the achievement and maintenance of a PSA of o0.2 ng/ml; giving a 5-year overall disease-free survival of 43%. Outcomes were equivalent for the adjuvant and salvage EBRT groups where therapeutic irradiation was administered when the serum PSA was o1.0 ng/ml. In 27 men receiving 60-67 Gy, Schild et al 48 reported 3-year progression-free survival of 76% with preradiotherapy PSA o1.1 ng/ml, compared with 26% for pretreatment PSA levels 41.1 ng/ml. Peschel et al reported a series of 52 men who had either adjuvant or salvage EBRT. He found the preoperative PSA level, the preradiotherapy PSA and seminal vesicle involvement were significant risk factors for actuarial biochemical recurrence following postoperative radiotherapy. However, the risk of recurrence was most significant for a preradiotherapy PSA of p0.3 ng/ml. 49 Van der Kooy et al 50 reported an 8-year relapse-free survival in 35 men receiving salvage radiotherapy alone of 67, 39 and 42% in patients with a PSA before treatment of p1.0, 1.1-4, and 44 ng/ml respectively.
The PSA cutoff to trigger salvage EBRT is variable; initiating salvage radiotherapy with a PSA o1.0 ng/ml is likely to confer the best chance of biochemical survival. 27, 50, 51 More data will be available on timing of salvage radiotherapy when two prospective randomised studies, European Organisation for Research and Treatment of Cancer (EORTC) 30943 and South West Oncology Group (SWOG) 8974 report.
The dose of radiation is important in terms of biochemical disease-free survival after salvage therapy. Several studies have shown a dose of 464.8 Gy is a significant prognostic factor for biochemical recurrencefree survival. 52 , 53 Valicenti et al reported a 3-year Salvage radiotherapy is usually well tolerated and toxicity has been markedly reduced by 3-D conformal techniques. Although there are no prospective quality of life studies reported, several studies demonstrate significant late genitourinary (GU) or rectal toxicity to be less than 10%. Using 3-D conformal EBRT, the groups from Michigan and Memorial Sloane-Kettering found grade X2 late GU toxicity of 6.3-10% and grade X2 rectal toxicity of 8.9-12%, respectively. 42, 44 The figures for the Michigan series were based on physician reporting and may have underestimated the actual complication rate. 54 Hormonal manipulation is used frequently in men with presumed or confirmed metastatic disease after radical prostatectomy, though there are insufficient data to support this therapy in men with PSA-only recurrence. No randomised study has been reported on the use of hormonal manipulation in lymph node negative men with biochemical failure after radical prostatectomy. The PSA level at which to institute therapy is unknown. Extrapolating from the major studies on hormonal manipulation in patients with advanced disease, hormonal therapy either alone or as maximum androgen blockade (oral antiandrogen and testicular ablation therapy), appears to have a small, but significant survival benefit, but more importantly reduces the risk of serious complications from disease progression. [55] [56] [57] The Medical Research Council (MRC) study demonstrated modest improvements in cancer-specific survival in the immediate vs delayed hormonal therapy men with M0, MX or M1 disease. 55 The greatest benefit was seen in men with M0 disease-which may most closely reflect the postradical prostatectomy patients with biochemical recurrence alone.
The question of whether hormonal manipulation reduces the risk of recurrent disease is currently being addressed by the Casodex Early Prostate Cancer Program (EPC). This has reported a relative reduction of 42% in clinical disease progression in all men with localised or locally advanced prostate cancer (T1-4, N0/ 1/x, M0), treated with bicalutamide 150 mg (Casodex, AstraZeneca) in conjunction with their standard treatment compared with standard treatment alone (9 vs 13.8%, respectively). 58 This was irrespective of stage or primary treatment, although the North American arm study, 23 which consisted of a greater proportion of radical prostatectomy patients, failed to show such significant differences in progression rates. These data are still immature; with a median treatment time of 2 years (range 1.8-2.5 years), it is unsurprising most men have responded to hormonal manipulation, whether this translates to an increase in survival as men inevitably become hormone refractory remains to be seen. A recent study comparing flutamide, another non-steroidal antiandrogen, vs no adjuvant treatment also found a reduction in rates of disease progression after radical prostatectomy. 59 However, following a median follow-up of 6.1 years, there were no differences in terms of overall survival and considerable toxicity was reported in the flutamide arm. Bicalutamide is well tolerated in advanced prostate cancer. 60, 61 Whether the favourable toxicity profile results in fewer withdrawals and enhanced efficacy remains to be seen.
The role of maximum androgen blockade or intermittent hormonal therapy remains contentious. The results of further studies, including the SWOG, NCI Canada and the EORTC GU-Group (NCI-INT 9346/ EORTC 30958), are required before these potentially beneficial developments become part of routine clinical practice.
Conclusions
The management of recurrent disease after radical prostatectomy will be greatly assisted by the publication of ongoing randomised studies. Still, a significant proportion of men undergoing surgery develop PSA relapse and many of these men may be cured by secondline therapies. Defining the population most likely to harbour local recurrence only is critical in deciding management strategies. Men with moderate grade disease (Gleason p7), who do not have nodal or seminal vesicle involvement, and develop a PSA relapse more than 1-2 years after surgery with a doubling time of 41 year and whose pre-treatment PSA is o1.5 ng/ml are most likely to benefit from local treatment with at least 64 Gy of salvage radiotherapy. Men with one or more poor prognostic features may be offered hormonal manipulation, the PSA level to initiate this treatment remains unknown. In all men, a balance must be made between exposing men to treatment with little proven survival benefit, but with associated unwanted effects and the patients' quality of life.
